Claims

1. Use of an inhibitor of Colony Stimulating Factor 1 receptor (CSF-1R) activity in the manufacture of a medicament for the treatment and/or prophylaxis of idiopathic pulmonary fibrosis (IPF), wherein the inhibitor is an anti-CSF-1R antibody or functionally active fragment or derivative thereof that binds to CSF-1R.
2. The use according to claim 1, wherein the antibody or fragment thereof is monoclonal, polyclonal, chimeric, humanised or bispecific.
3. The use according to claim 1 or claim 2 wherein the antibody fragment is a Fab, Fab', $F(ab')_2$, scFv or an epitope-binding fragment thereof.
4. The use according to any one of claims 1-3 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).